Amtagvi

Overview

lifileucel

autologous cellular immunotherapy

• antiplatelet effects
• immunomodulatory effects (other)
• myelosuppressive oncologic agent
• nephrotoxicity
• tachycardia

Contraindicated

• cidofovir
Amtagvi (lifileucel)

+

cidofovir

1 interaction

Contraindicated

lifileucel + cidofovir

contraindicated; D/C lifileucel at least 7 days prior to cidofovir tx: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Avoid/Use Alternative

• alteplase
Amtagvi (lifileucel)

+

alteplase

1 interaction

Avoid/Use Alternative

lifileucel + alteplase

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• amikacin
Amtagvi (lifileucel)

+

amikacin

1 interaction

Avoid/Use Alternative

lifileucel + amikacin

use alternative or monitor amikacin levels, renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• amikacin inhaled
Amtagvi (lifileucel)

+

amikacin inhaled

1 interaction

Avoid/Use Alternative

lifileucel + amikacin inhaled

use alternative or monitor renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• anti-thymocyte globulin
Amtagvi (lifileucel)

+

anti-thymocyte globulin

1 interaction

Avoid/Use Alternative

lifileucel + anti-thymocyte globulin

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression (antagonistic effects; additive effects)

• antithrombin
Amtagvi (lifileucel)

+

antithrombin

1 interaction

Avoid/Use Alternative

lifileucel + antithrombin

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• apixaban
Amtagvi (lifileucel)

+

apixaban

1 interaction

Avoid/Use Alternative

lifileucel + apixaban

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• argatroban
Amtagvi (lifileucel)

+

argatroban

1 interaction

Avoid/Use Alternative

lifileucel + argatroban

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• azathioprine
Amtagvi (lifileucel)

+

azathioprine

1 interaction

Avoid/Use Alternative

lifileucel + azathioprine

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression (antagonistic effects; additive effects)

• basiliximab
Amtagvi (lifileucel)

+

basiliximab

1 interaction

Avoid/Use Alternative

lifileucel + basiliximab

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• belatacept
Amtagvi (lifileucel)

+

belatacept

1 interaction

Avoid/Use Alternative

lifileucel + belatacept

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• betamethasone
Amtagvi (lifileucel)

+

betamethasone

1 interaction

Avoid/Use Alternative

lifileucel + betamethasone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• bivalirudin
Amtagvi (lifileucel)

+

bivalirudin

1 interaction

Avoid/Use Alternative

lifileucel + bivalirudin

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• budesonide
Amtagvi (lifileucel)

+

budesonide

1 interaction

Avoid/Use Alternative

lifileucel + budesonide

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• budesonide rectal
Amtagvi (lifileucel)

+

budesonide rectal

1 interaction

Avoid/Use Alternative

lifileucel + budesonide rectal

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• chloramphenicol
Amtagvi (lifileucel)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

lifileucel + chloramphenicol

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cladribine oral
Amtagvi (lifileucel)

+

cladribine oral

1 interaction

Avoid/Use Alternative

lifileucel + cladribine oral

use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• clofarabine
Amtagvi (lifileucel)

+

clofarabine

1 interaction

Avoid/Use Alternative

lifileucel + clofarabine

avoid lifileucel during 5 day clofarabine tx; monitor CBC, renal fxn, BP: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, hypotension, other adverse effects (additive effects)

• cortisone
Amtagvi (lifileucel)

+

cortisone

1 interaction

Avoid/Use Alternative

lifileucel + cortisone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• cyclosporine
Amtagvi (lifileucel)

+

cyclosporine

1 interaction

Avoid/Use Alternative

lifileucel + cyclosporine

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, nephrotoxicity (antagonistic effects; additive effects)

• dabigatran
Amtagvi (lifileucel)

+

dabigatran

1 interaction

Avoid/Use Alternative

lifileucel + dabigatran

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• dalteparin
Amtagvi (lifileucel)

+

dalteparin

1 interaction

Avoid/Use Alternative

lifileucel + dalteparin

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• deferiprone
Amtagvi (lifileucel)

+

deferiprone

1 interaction

Avoid/Use Alternative

lifileucel + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• defibrotide
Amtagvi (lifileucel)

+

defibrotide

1 interaction

Avoid/Use Alternative

lifileucel + defibrotide

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• deflazacort
Amtagvi (lifileucel)

+

deflazacort

1 interaction

Avoid/Use Alternative

lifileucel + deflazacort

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• dexamethasone
Amtagvi (lifileucel)

+

dexamethasone

1 interaction

Avoid/Use Alternative

lifileucel + dexamethasone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• dexrazoxane
Amtagvi (lifileucel)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

lifileucel + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemotx (additive effects; mechanism unknown)

• edoxaban
Amtagvi (lifileucel)

+

edoxaban

1 interaction

Avoid/Use Alternative

lifileucel + edoxaban

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• enoxaparin
Amtagvi (lifileucel)

+

enoxaparin

1 interaction

Avoid/Use Alternative

lifileucel + enoxaparin

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ephedra
Amtagvi (lifileucel)

+

ephedra

1 interaction

Avoid/Use Alternative

lifileucel + ephedra

avoid combo: combo may incr. risk of tachycardia (additive effects)

• epinephrine inhaled
Amtagvi (lifileucel)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

lifileucel + epinephrine inhaled

avoid combo: combo may incr. risk of tachycardia (additive effects)

• everolimus
Amtagvi (lifileucel)

+

everolimus

1 interaction

Avoid/Use Alternative

lifileucel + everolimus

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression, nephrotoxicity (antagonistic effects; additive effects)

• fexinidazole
Amtagvi (lifileucel)

+

fexinidazole

1 interaction

Avoid/Use Alternative

lifileucel + fexinidazole

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludrocortisone
Amtagvi (lifileucel)

+

fludrocortisone

1 interaction

Avoid/Use Alternative

lifileucel + fludrocortisone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• fondaparinux
Amtagvi (lifileucel)

+

fondaparinux

1 interaction

Avoid/Use Alternative

lifileucel + fondaparinux

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• foscarnet
Amtagvi (lifileucel)

+

foscarnet

1 interaction

Avoid/Use Alternative

lifileucel + foscarnet

use alternative or monitor CBC, renal fxn: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• ganciclovir
Amtagvi (lifileucel)

+

ganciclovir

1 interaction

Avoid/Use Alternative

lifileucel + ganciclovir

use alternative or monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• gentamicin
Amtagvi (lifileucel)

+

gentamicin

1 interaction

Avoid/Use Alternative

lifileucel + gentamicin

use alternative or monitor gentamicin levels, renal fxn, ototoxicity: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• heparin
Amtagvi (lifileucel)

+

heparin

1 interaction

Avoid/Use Alternative

lifileucel + heparin

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• hydrocortisone
Amtagvi (lifileucel)

+

hydrocortisone

1 interaction

Avoid/Use Alternative

lifileucel + hydrocortisone

avoid combo: combo may incr. risk of serious infection, GI or other bleeding, incl. life-threatening; may decr. lifileucel efficacy (additive effects; antagonistic effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Amtagvi (lifileucel)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Avoid/Use Alternative

lifileucel + lymphocyte immune globulin, anti-thymocyte globulin

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression (antagonistic effects; additive effects)

• methotrexate
Amtagvi (lifileucel)

+

methotrexate

1 interaction

Avoid/Use Alternative

lifileucel + methotrexate

consider alternative or monitor CBC, renal fxn, bleeding s/sx: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, GI or other bleeding (incl. life-threatening), other adverse effects (additive effects)

• methylprednisolone
Amtagvi (lifileucel)

+

methylprednisolone

1 interaction

Avoid/Use Alternative

lifileucel + methylprednisolone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• mycophenolate mofetil
Amtagvi (lifileucel)

+

mycophenolate mofetil

1 interaction

Avoid/Use Alternative

lifileucel + mycophenolate mofetil

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression, GI or other bleeding, incl. life-threatening (antagonistic effects; additive effects)

• mycophenolic acid
Amtagvi (lifileucel)

+

mycophenolic acid

1 interaction

Avoid/Use Alternative

lifileucel + mycophenolic acid

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression, GI or other bleeding, incl. life-threatening (antagonistic effects; additive effects)

• natalizumab
Amtagvi (lifileucel)

+

natalizumab

1 interaction

Avoid/Use Alternative

lifileucel + natalizumab

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• oxaliplatin
Amtagvi (lifileucel)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

lifileucel + oxaliplatin

use alternative or monitor ECG, CBC, renal fxn, ototoxicity: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, GI or other bleeding (incl. life-threatening), auditory, vestibular, other adverse effects (additive effects)

• palifermin
Amtagvi (lifileucel)

+

palifermin

1 interaction

Avoid/Use Alternative

lifileucel + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• penicillamine
Amtagvi (lifileucel)

+

penicillamine

1 interaction

Avoid/Use Alternative

lifileucel + penicillamine

use alternative or monitor CBC, renal fxn: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• pentamidine
Amtagvi (lifileucel)

+

pentamidine

1 interaction

Avoid/Use Alternative

lifileucel + pentamidine

use alternative or monitor CBC, renal fxn: combo may incr. risk of myelosuppression, nephrotoxicity (additive effects)

• polymyxin B
Amtagvi (lifileucel)

+

polymyxin B

1 interaction

Avoid/Use Alternative

lifileucel + polymyxin B

avoid combo: combo may incr. risk of nephrotoxicity (additive effects)

• prednisolone
Amtagvi (lifileucel)

+

prednisolone

1 interaction

Avoid/Use Alternative

lifileucel + prednisolone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• prednisone
Amtagvi (lifileucel)

+

prednisone

1 interaction

Avoid/Use Alternative

lifileucel + prednisone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• primaquine
Amtagvi (lifileucel)

+

primaquine

1 interaction

Avoid/Use Alternative

lifileucel + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• radium Ra 223 dichloride
Amtagvi (lifileucel)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

lifileucel + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• reteplase
Amtagvi (lifileucel)

+

reteplase

1 interaction

Avoid/Use Alternative

lifileucel + reteplase

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• rivaroxaban
Amtagvi (lifileucel)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

lifileucel + rivaroxaban

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ropeginterferon alfa-2b
Amtagvi (lifileucel)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

lifileucel + ropeginterferon alfa-2b

use alternative or monitor CBC, renal fxn: combo may incr. risk of serious infection, myelosuppression, nephrotoxicity (additive effects)

• sirolimus
Amtagvi (lifileucel)

+

sirolimus

1 interaction

Avoid/Use Alternative

lifileucel + sirolimus

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, myelosuppression, nephrotoxicity (antagonistic effects; additive effects)

• streptomycin
Amtagvi (lifileucel)

+

streptomycin

1 interaction

Avoid/Use Alternative

lifileucel + streptomycin

use alternative or monitor renal fxn, ototoxicity: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• streptozocin
Amtagvi (lifileucel)

+

streptozocin

1 interaction

Avoid/Use Alternative

lifileucel + streptozocin

use alternative or monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• tacrolimus
Amtagvi (lifileucel)

+

tacrolimus

1 interaction

Avoid/Use Alternative

lifileucel + tacrolimus

avoid combo: combo may decr. lifileucel efficacy; may incr. tacrolimus levels, risk of nephrotoxicity, serious infection, other adverse effects (antagonistic effects; additive effects)

• tenecteplase
Amtagvi (lifileucel)

+

tenecteplase

1 interaction

Avoid/Use Alternative

lifileucel + tenecteplase

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tenofovir disoproxil
Amtagvi (lifileucel)

+

tenofovir disoproxil

1 interaction

Avoid/Use Alternative

lifileucel + tenofovir disoproxil

use alternative or monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• tobramycin
Amtagvi (lifileucel)

+

tobramycin

1 interaction

Avoid/Use Alternative

lifileucel + tobramycin

use alternative or monitor tobramycin levels, renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• tobramycin inhaled
Amtagvi (lifileucel)

+

tobramycin inhaled

1 interaction

Avoid/Use Alternative

lifileucel + tobramycin inhaled

use alternative or monitor renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• triamcinolone
Amtagvi (lifileucel)

+

triamcinolone

1 interaction

Avoid/Use Alternative

lifileucel + triamcinolone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• valganciclovir
Amtagvi (lifileucel)

+

valganciclovir

1 interaction

Avoid/Use Alternative

lifileucel + valganciclovir

use alternative or monitor CBC, renal fxn: combo may incr. valganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• vamorolone
Amtagvi (lifileucel)

+

vamorolone

1 interaction

Avoid/Use Alternative

lifileucel + vamorolone

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection (antagonistic effects; additive effects)

• voclosporin
Amtagvi (lifileucel)

+

voclosporin

1 interaction

Avoid/Use Alternative

lifileucel + voclosporin

avoid combo: combo may decr. lifileucel efficacy; may incr. risk of serious infection, nephrotoxicity (antagonistic effects; additive effects)

• warfarin
Amtagvi (lifileucel)

+

warfarin

1 interaction

Avoid/Use Alternative

lifileucel + warfarin

use alternative or monitor INR, bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (synergistic effects)

Monitor/Modify Tx

• abrocitinib
Amtagvi (lifileucel)

+

abrocitinib

1 interaction

Monitor/Modify Tx

lifileucel + abrocitinib

monitor platelets, bleeding s/sx, especially during abrocitinib tx initiation or if abrocitinib 200 mg/day: combo may incr. risk of serious infection, bleeding, incl. life-threatening (additive effects)

• acalabrutinib
Amtagvi (lifileucel)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

lifileucel + acalabrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• acyclovir
Amtagvi (lifileucel)

+

acyclovir

1 interaction

Monitor/Modify Tx

lifileucel + acyclovir

monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• adefovir dipivoxil
Amtagvi (lifileucel)

+

adefovir dipivoxil

1 interaction

Monitor/Modify Tx

lifileucel + adefovir dipivoxil

monitor renal fxn: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased by nephrotoxic agents, additive effects)

• ado-trastuzumab emtansine
Amtagvi (lifileucel)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

lifileucel + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• afatinib
Amtagvi (lifileucel)

+

afatinib

1 interaction

Monitor/Modify Tx

lifileucel + afatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• albendazole
Amtagvi (lifileucel)

+

albendazole

1 interaction

Monitor/Modify Tx

lifileucel + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• albuterol
Amtagvi (lifileucel)

+

albuterol

1 interaction

Monitor/Modify Tx

lifileucel + albuterol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• albuterol inhaled
Amtagvi (lifileucel)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + albuterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• alectinib
Amtagvi (lifileucel)

+

alectinib

1 interaction

Monitor/Modify Tx

lifileucel + alectinib

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• alemtuzumab
Amtagvi (lifileucel)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

lifileucel + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of serious infection, myelosuppression (additive effects)

• allopurinol
Amtagvi (lifileucel)

+

allopurinol

1 interaction

Monitor/Modify Tx

lifileucel + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• amitriptyline
Amtagvi (lifileucel)

+

amitriptyline

1 interaction

Monitor/Modify Tx

lifileucel + amitriptyline

monitor HR: combo may incr. risk of tachycardia (additive effects)

• amoxapine
Amtagvi (lifileucel)

+

amoxapine

1 interaction

Monitor/Modify Tx

lifileucel + amoxapine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• amphetamine
Amtagvi (lifileucel)

+

amphetamine

1 interaction

Monitor/Modify Tx

lifileucel + amphetamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• amphotericin
Amtagvi (lifileucel)

+

amphotericin

1 interaction

Monitor/Modify Tx

lifileucel + amphotericin

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• anacaulase topical
Amtagvi (lifileucel)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

lifileucel + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• anagrelide
Amtagvi (lifileucel)

+

anagrelide

1 interaction

Monitor/Modify Tx

lifileucel + anagrelide

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• anthrax immune globulin
Amtagvi (lifileucel)

+

anthrax immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + anthrax immune globulin

monitor renal fxn; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• arformoterol inhaled
Amtagvi (lifileucel)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + arformoterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• armodafinil
Amtagvi (lifileucel)

+

armodafinil

1 interaction

Monitor/Modify Tx

lifileucel + armodafinil

monitor HR: combo may incr. risk of tachycardia (additive effects)

• asenapine
Amtagvi (lifileucel)

+

asenapine

1 interaction

Monitor/Modify Tx

lifileucel + asenapine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• asparaginase
Amtagvi (lifileucel)

+

asparaginase

1 interaction

Monitor/Modify Tx

lifileucel + asparaginase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• aspirin
Amtagvi (lifileucel)

+

aspirin

1 interaction

Monitor/Modify Tx

lifileucel + aspirin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• atidarsagene autotemcel
Amtagvi (lifileucel)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

lifileucel + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

• atomoxetine
Amtagvi (lifileucel)

+

atomoxetine

1 interaction

Monitor/Modify Tx

lifileucel + atomoxetine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• atropine
Amtagvi (lifileucel)

+

atropine

1 interaction

Monitor/Modify Tx

lifileucel + atropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• auranofin
Amtagvi (lifileucel)

+

auranofin

1 interaction

Monitor/Modify Tx

lifileucel + auranofin

monitor CBC, renal fxn: combo may incr. auranofin levels, risk of nephrotoxicity, myelosuppression, other adverse effects (additive effects)

• avapritinib
Amtagvi (lifileucel)

+

avapritinib

1 interaction

Monitor/Modify Tx

lifileucel + avapritinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• axitinib
Amtagvi (lifileucel)

+

axitinib

1 interaction

Monitor/Modify Tx

lifileucel + axitinib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• balsalazide
Amtagvi (lifileucel)

+

balsalazide

1 interaction

Monitor/Modify Tx

lifileucel + balsalazide

monitor CBC, renal fxn: combo may incr. risk of myelosuppression, nephrotoxicity (additive effects)

• baricitinib
Amtagvi (lifileucel)

+

baricitinib

1 interaction

Monitor/Modify Tx

lifileucel + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Amtagvi (lifileucel)

+

benznidazole

1 interaction

Monitor/Modify Tx

lifileucel + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benzphetamine
Amtagvi (lifileucel)

+

benzphetamine

1 interaction

Monitor/Modify Tx

lifileucel + benzphetamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• benztropine
Amtagvi (lifileucel)

+

benztropine

1 interaction

Monitor/Modify Tx

lifileucel + benztropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• betibeglogene autotemcel
Amtagvi (lifileucel)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

lifileucel + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Amtagvi (lifileucel)

+

bevacizumab

1 interaction

Monitor/Modify Tx

lifileucel + bevacizumab

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• binimetinib
Amtagvi (lifileucel)

+

binimetinib

1 interaction

Monitor/Modify Tx

lifileucel + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bleomycin
Amtagvi (lifileucel)

+

bleomycin

1 interaction

Monitor/Modify Tx

lifileucel + bleomycin

monitor renal fxn; decr. bleomycin dose based on CrCl: combo may incr. bleomycin levels, risk of pulmonary toxicities (incl. life-threatening), other adverse effects (renal excretion decreased)

• botulism immune globulin
Amtagvi (lifileucel)

+

botulism immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + botulism immune globulin

monitor renal fxn; use lowest botulism immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• brentuximab vedotin
Amtagvi (lifileucel)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

lifileucel + brentuximab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bromelain
Amtagvi (lifileucel)

+

bromelain

1 interaction

Monitor/Modify Tx

lifileucel + bromelain

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• bromfenac ophthalmic
Amtagvi (lifileucel)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• cabazitaxel
Amtagvi (lifileucel)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

lifileucel + cabazitaxel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cabozantinib
Amtagvi (lifileucel)

+

cabozantinib

1 interaction

Monitor/Modify Tx

lifileucel + cabozantinib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• caffeine
Amtagvi (lifileucel)

+

caffeine

1 interaction

Monitor/Modify Tx

lifileucel + caffeine

monitor HR; avoid excessive caffeine intake: combo may incr. risk of tachycardia (additive effects)

• caffeine citrate
Amtagvi (lifileucel)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

lifileucel + caffeine citrate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• calaspargase
Amtagvi (lifileucel)

+

calaspargase

1 interaction

Monitor/Modify Tx

lifileucel + calaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cangrelor
Amtagvi (lifileucel)

+

cangrelor

1 interaction

Monitor/Modify Tx

lifileucel + cangrelor

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cannabis
Amtagvi (lifileucel)

+

cannabis

1 interaction

Monitor/Modify Tx

lifileucel + cannabis

monitor HR: combo may incr. risk of tachycardia (additive effects)

• capecitabine
Amtagvi (lifileucel)

+

capecitabine

1 interaction

Monitor/Modify Tx

lifileucel + capecitabine

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• caplacizumab
Amtagvi (lifileucel)

+

caplacizumab

1 interaction

Monitor/Modify Tx

lifileucel + caplacizumab

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• carboplatin
Amtagvi (lifileucel)

+

carboplatin

1 interaction

Monitor/Modify Tx

lifileucel + carboplatin

monitor CBC, renal fxn, ototoxicity: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• carfilzomib
Amtagvi (lifileucel)

+

carfilzomib

1 interaction

Monitor/Modify Tx

lifileucel + carfilzomib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• celecoxib
Amtagvi (lifileucel)

+

celecoxib

1 interaction

Monitor/Modify Tx

lifileucel + celecoxib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cilostazol
Amtagvi (lifileucel)

+

cilostazol

1 interaction

Monitor/Modify Tx

lifileucel + cilostazol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cisplatin
Amtagvi (lifileucel)

+

cisplatin

1 interaction

Monitor/Modify Tx

lifileucel + cisplatin

monitor CBC, renal fxn, ototoxicity: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• citalopram
Amtagvi (lifileucel)

+

citalopram

1 interaction

Monitor/Modify Tx

lifileucel + citalopram

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• clindamycin
Amtagvi (lifileucel)

+

clindamycin

1 interaction

Monitor/Modify Tx

lifileucel + clindamycin

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• clomipramine
Amtagvi (lifileucel)

+

clomipramine

1 interaction

Monitor/Modify Tx

lifileucel + clomipramine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• clopidogrel
Amtagvi (lifileucel)

+

clopidogrel

1 interaction

Monitor/Modify Tx

lifileucel + clopidogrel

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• clozapine
Amtagvi (lifileucel)

+

clozapine

1 interaction

Monitor/Modify Tx

lifileucel + clozapine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cocaine
Amtagvi (lifileucel)

+

cocaine

1 interaction

Monitor/Modify Tx

lifileucel + cocaine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• colchicine
Amtagvi (lifileucel)

+

colchicine

1 interaction

Monitor/Modify Tx

lifileucel + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• colistimethate
Amtagvi (lifileucel)

+

colistimethate

1 interaction

Monitor/Modify Tx

lifileucel + colistimethate

monitor renal fxn: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

• collagenase clostridium histolyticum
Amtagvi (lifileucel)

+

collagenase clostridium histolyticum

1 interaction

Monitor/Modify Tx

lifileucel + collagenase clostridium histolyticum

monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, incl. severe (additive effects)

• creatine
Amtagvi (lifileucel)

+

creatine

1 interaction

Monitor/Modify Tx

lifileucel + creatine

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• cyclophosphamide
Amtagvi (lifileucel)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

lifileucel + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

• cysteamine
Amtagvi (lifileucel)

+

cysteamine

1 interaction

Monitor/Modify Tx

lifileucel + cysteamine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cytomegalovirus immune globulin
Amtagvi (lifileucel)

+

cytomegalovirus immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + cytomegalovirus immune globulin

monitor renal fxn; use lowest cytomegalovirus immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• danshen
Amtagvi (lifileucel)

+

danshen

1 interaction

Monitor/Modify Tx

lifileucel + danshen

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• dapsone
Amtagvi (lifileucel)

+

dapsone

1 interaction

Monitor/Modify Tx

lifileucel + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dasatinib
Amtagvi (lifileucel)

+

dasatinib

1 interaction

Monitor/Modify Tx

lifileucel + dasatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• deferasirox
Amtagvi (lifileucel)

+

deferasirox

1 interaction

Monitor/Modify Tx

lifileucel + deferasirox

monitor CBC, renal fxn, ototoxicity, bleeding s/sx: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, GI or other bleeding (incl. life-threatening), auditory, vestibular, other adverse effects (additive effects)

• deferoxamine
Amtagvi (lifileucel)

+

deferoxamine

1 interaction

Monitor/Modify Tx

lifileucel + deferoxamine

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• desipramine
Amtagvi (lifileucel)

+

desipramine

1 interaction

Monitor/Modify Tx

lifileucel + desipramine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• desvenlafaxine
Amtagvi (lifileucel)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

lifileucel + desvenlafaxine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Amtagvi (lifileucel)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

lifileucel + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection, GI or other bleeding, incl. life-threatening (additive effects)

• dexmethylphenidate
Amtagvi (lifileucel)

+

dexmethylphenidate

1 interaction

Monitor/Modify Tx

lifileucel + dexmethylphenidate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• dextroamphetamine
Amtagvi (lifileucel)

+

dextroamphetamine

1 interaction

Monitor/Modify Tx

lifileucel + dextroamphetamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diclofenac
Amtagvi (lifileucel)

+

diclofenac

1 interaction

Monitor/Modify Tx

lifileucel + diclofenac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diclofenac ophthalmic
Amtagvi (lifileucel)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Amtagvi (lifileucel)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

lifileucel + diclofenac topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dicyclomine
Amtagvi (lifileucel)

+

dicyclomine

1 interaction

Monitor/Modify Tx

lifileucel + dicyclomine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diethylpropion
Amtagvi (lifileucel)

+

diethylpropion

1 interaction

Monitor/Modify Tx

lifileucel + diethylpropion

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diflunisal
Amtagvi (lifileucel)

+

diflunisal

1 interaction

Monitor/Modify Tx

lifileucel + diflunisal

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dimethyl fumarate
Amtagvi (lifileucel)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

lifileucel + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of serious infection, GI or other bleeding, incl. life-threatening (additive effects)

• diosmin
Amtagvi (lifileucel)

+

diosmin

1 interaction

Monitor/Modify Tx

lifileucel + diosmin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• dipyridamole
Amtagvi (lifileucel)

+

dipyridamole

1 interaction

Monitor/Modify Tx

lifileucel + dipyridamole

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• diroximel fumarate
Amtagvi (lifileucel)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

lifileucel + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of serious infection, GI or other bleeding, incl. life-threatening (additive effects)

• dobutamine
Amtagvi (lifileucel)

+

dobutamine

1 interaction

Monitor/Modify Tx

lifileucel + dobutamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• dopamine
Amtagvi (lifileucel)

+

dopamine

1 interaction

Monitor/Modify Tx

lifileucel + dopamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• doxepin
Amtagvi (lifileucel)

+

doxepin

1 interaction

Monitor/Modify Tx

lifileucel + doxepin

monitor HR: combo may incr. risk of tachycardia (additive effects)

• dronabinol
Amtagvi (lifileucel)

+

dronabinol

1 interaction

Monitor/Modify Tx

lifileucel + dronabinol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• duloxetine
Amtagvi (lifileucel)

+

duloxetine

1 interaction

Monitor/Modify Tx

lifileucel + duloxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• efbemalenograstim alfa
Amtagvi (lifileucel)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

lifileucel + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Amtagvi (lifileucel)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

lifileucel + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elivaldogene autotemcel
Amtagvi (lifileucel)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

lifileucel + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

• encorafenib
Amtagvi (lifileucel)

+

encorafenib

1 interaction

Monitor/Modify Tx

lifileucel + encorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ephedrine injection
Amtagvi (lifileucel)

+

ephedrine injection

1 interaction

Monitor/Modify Tx

lifileucel + ephedrine injection

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ephedrine oral
Amtagvi (lifileucel)

+

ephedrine oral

1 interaction

Monitor/Modify Tx

lifileucel + ephedrine oral

monitor HR: combo may incr. risk of tachycardia (additive effects)

• epinephrine
Amtagvi (lifileucel)

+

epinephrine

1 interaction

Monitor/Modify Tx

lifileucel + epinephrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• epoprostenol
Amtagvi (lifileucel)

+

epoprostenol

1 interaction

Monitor/Modify Tx

lifileucel + epoprostenol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• eptifibatide
Amtagvi (lifileucel)

+

eptifibatide

1 interaction

Monitor/Modify Tx

lifileucel + eptifibatide

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• erlotinib
Amtagvi (lifileucel)

+

erlotinib

1 interaction

Monitor/Modify Tx

lifileucel + erlotinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• escitalopram
Amtagvi (lifileucel)

+

escitalopram

1 interaction

Monitor/Modify Tx

lifileucel + escitalopram

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• ethanol
Amtagvi (lifileucel)

+

ethanol

1 interaction

Monitor/Modify Tx

lifileucel + ethanol

monitor bleeding s/sx w/ orally ingested alcohol: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• etodolac
Amtagvi (lifileucel)

+

etodolac

1 interaction

Monitor/Modify Tx

lifileucel + etodolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• evening primrose oil
Amtagvi (lifileucel)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

lifileucel + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• exagamglogene autotemcel
Amtagvi (lifileucel)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

lifileucel + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fenoprofen
Amtagvi (lifileucel)

+

fenoprofen

1 interaction

Monitor/Modify Tx

lifileucel + fenoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• fenugreek
Amtagvi (lifileucel)

+

fenugreek

1 interaction

Monitor/Modify Tx

lifileucel + fenugreek

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• filgrastim (G-CSF)
Amtagvi (lifileucel)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

lifileucel + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• flucytosine
Amtagvi (lifileucel)

+

flucytosine

1 interaction

Monitor/Modify Tx

lifileucel + flucytosine

monitor CBC, renal fxn, flucytosine levels: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• fluoxetine
Amtagvi (lifileucel)

+

fluoxetine

1 interaction

Monitor/Modify Tx

lifileucel + fluoxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fluphenazine
Amtagvi (lifileucel)

+

fluphenazine

1 interaction

Monitor/Modify Tx

lifileucel + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flurbiprofen
Amtagvi (lifileucel)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

lifileucel + flurbiprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• flurbiprofen ophthalmic
Amtagvi (lifileucel)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• fluvoxamine
Amtagvi (lifileucel)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

lifileucel + fluvoxamine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• formoterol inhaled
Amtagvi (lifileucel)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + formoterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• fostamatinib
Amtagvi (lifileucel)

+

fostamatinib

1 interaction

Monitor/Modify Tx

lifileucel + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fruquintinib
Amtagvi (lifileucel)

+

fruquintinib

1 interaction

Monitor/Modify Tx

lifileucel + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• garlic
Amtagvi (lifileucel)

+

garlic

1 interaction

Monitor/Modify Tx

lifileucel + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• gefitinib
Amtagvi (lifileucel)

+

gefitinib

1 interaction

Monitor/Modify Tx

lifileucel + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• gemtuzumab ozogamicin
Amtagvi (lifileucel)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

lifileucel + gemtuzumab ozogamicin

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ginkgo
Amtagvi (lifileucel)

+

ginkgo

1 interaction

Monitor/Modify Tx

lifileucel + ginkgo

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• givinostat
Amtagvi (lifileucel)

+

givinostat

1 interaction

Monitor/Modify Tx

lifileucel + givinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glycopyrrolate
Amtagvi (lifileucel)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

lifileucel + glycopyrrolate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• hoodia
Amtagvi (lifileucel)

+

hoodia

1 interaction

Monitor/Modify Tx

lifileucel + hoodia

monitor HR: combo may incr. risk of tachycardia (additive effects)

• hydroxychloroquine
Amtagvi (lifileucel)

+

hydroxychloroquine

1 interaction

Monitor/Modify Tx

lifileucel + hydroxychloroquine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyurea
Amtagvi (lifileucel)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

lifileucel + hydroxyurea

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• hyoscyamine
Amtagvi (lifileucel)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

lifileucel + hyoscyamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ibrutinib
Amtagvi (lifileucel)

+

ibrutinib

1 interaction

Monitor/Modify Tx

lifileucel + ibrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ibuprofen
Amtagvi (lifileucel)

+

ibuprofen

1 interaction

Monitor/Modify Tx

lifileucel + ibuprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibuprofen lysine
Amtagvi (lifileucel)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

lifileucel + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• icosapent ethyl
Amtagvi (lifileucel)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

lifileucel + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ifosfamide
Amtagvi (lifileucel)

+

ifosfamide

1 interaction

Monitor/Modify Tx

lifileucel + ifosfamide

monitor CBC, renal, cardiac fxn: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

• iloperidone
Amtagvi (lifileucel)

+

iloperidone

1 interaction

Monitor/Modify Tx

lifileucel + iloperidone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• iloprost inhaled
Amtagvi (lifileucel)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

lifileucel + iloprost inhaled

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• imatinib
Amtagvi (lifileucel)

+

imatinib

1 interaction

Monitor/Modify Tx

lifileucel + imatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• imipramine
Amtagvi (lifileucel)

+

imipramine

1 interaction

Monitor/Modify Tx

lifileucel + imipramine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• immune globulin
Amtagvi (lifileucel)

+

immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + immune globulin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• indomethacin
Amtagvi (lifileucel)

+

indomethacin

1 interaction

Monitor/Modify Tx

lifileucel + indomethacin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• interferon beta 1a
Amtagvi (lifileucel)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

lifileucel + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Amtagvi (lifileucel)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

lifileucel + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Amtagvi (lifileucel)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

lifileucel + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• iohexol
Amtagvi (lifileucel)

+

iohexol

1 interaction

Monitor/Modify Tx

lifileucel + iohexol

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• iopamidol
Amtagvi (lifileucel)

+

iopamidol

1 interaction

Monitor/Modify Tx

lifileucel + iopamidol

if IV iopamidol use, monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• isoproterenol
Amtagvi (lifileucel)

+

isoproterenol

1 interaction

Monitor/Modify Tx

lifileucel + isoproterenol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ketamine
Amtagvi (lifileucel)

+

ketamine

1 interaction

Monitor/Modify Tx

lifileucel + ketamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ketoprofen
Amtagvi (lifileucel)

+

ketoprofen

1 interaction

Monitor/Modify Tx

lifileucel + ketoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac
Amtagvi (lifileucel)

+

ketorolac

1 interaction

Monitor/Modify Tx

lifileucel + ketorolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac ophthalmic
Amtagvi (lifileucel)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• leflunomide
Amtagvi (lifileucel)

+

leflunomide

1 interaction

Monitor/Modify Tx

lifileucel + leflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• lenvatinib
Amtagvi (lifileucel)

+

lenvatinib

1 interaction

Monitor/Modify Tx

lifileucel + lenvatinib

monitor renal fxn, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• levalbuterol inhaled
Amtagvi (lifileucel)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + levalbuterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• levomilnacipran
Amtagvi (lifileucel)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

lifileucel + levomilnacipran

monitor HR, bleeding s/sx: combo may incr. risk of tachycardia, bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• linezolid
Amtagvi (lifileucel)

+

linezolid

1 interaction

Monitor/Modify Tx

lifileucel + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• liraglutide
Amtagvi (lifileucel)

+

liraglutide

1 interaction

Monitor/Modify Tx

lifileucel + liraglutide

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• lisdexamfetamine
Amtagvi (lifileucel)

+

lisdexamfetamine

1 interaction

Monitor/Modify Tx

lifileucel + lisdexamfetamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• lithium
Amtagvi (lifileucel)

+

lithium

1 interaction

Monitor/Modify Tx

lifileucel + lithium

monitor lithium levels, renal fxn: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

• lonafarnib
Amtagvi (lifileucel)

+

lonafarnib

1 interaction

Monitor/Modify Tx

lifileucel + lonafarnib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lovotibeglogene autotemcel
Amtagvi (lifileucel)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

lifileucel + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Amtagvi (lifileucel)

+

lumateperone

1 interaction

Monitor/Modify Tx

lifileucel + lumateperone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lutetium Lu 177 vipivotide tetraxetan
Amtagvi (lifileucel)

+

lutetium Lu 177 vipivotide tetraxetan

1 interaction

Monitor/Modify Tx

lifileucel + lutetium Lu 177 vipivotide tetraxetan

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• magnesium salicylate
Amtagvi (lifileucel)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

lifileucel + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meclofenamate
Amtagvi (lifileucel)

+

meclofenamate

1 interaction

Monitor/Modify Tx

lifileucel + meclofenamate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mefenamic acid
Amtagvi (lifileucel)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

lifileucel + mefenamic acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meloxicam
Amtagvi (lifileucel)

+

meloxicam

1 interaction

Monitor/Modify Tx

lifileucel + meloxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mercaptopurine
Amtagvi (lifileucel)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

lifileucel + mercaptopurine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mesalamine
Amtagvi (lifileucel)

+

mesalamine

1 interaction

Monitor/Modify Tx

lifileucel + mesalamine

monitor CBC, renal fxn: combo may incr. risk of nephrotoxicity, myelosuppression (additive effects)

• mesalamine rectal
Amtagvi (lifileucel)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

lifileucel + mesalamine rectal

monitor CBC, renal fxn: combo may incr. risk of myelosuppression, nephrotoxicity (additive effects)

• methamphetamine
Amtagvi (lifileucel)

+

methamphetamine

1 interaction

Monitor/Modify Tx

lifileucel + methamphetamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• methscopolamine
Amtagvi (lifileucel)

+

methscopolamine

1 interaction

Monitor/Modify Tx

lifileucel + methscopolamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• methyl salicylate topical
Amtagvi (lifileucel)

+

methyl salicylate topical

1 interaction

Monitor/Modify Tx

lifileucel + methyl salicylate topical

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, systemic salicylate absorption may occur from topical use)

• methylphenidate
Amtagvi (lifileucel)

+

methylphenidate

1 interaction

Monitor/Modify Tx

lifileucel + methylphenidate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• milnacipran
Amtagvi (lifileucel)

+

milnacipran

1 interaction

Monitor/Modify Tx

lifileucel + milnacipran

monitor HR, bleeding s/sx: combo may incr. risk of tachycardia, bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• mitomycin
Amtagvi (lifileucel)

+

mitomycin

1 interaction

Monitor/Modify Tx

lifileucel + mitomycin

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• mitotane
Amtagvi (lifileucel)

+

mitotane

1 interaction

Monitor/Modify Tx

lifileucel + mitotane

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• modafinil
Amtagvi (lifileucel)

+

modafinil

1 interaction

Monitor/Modify Tx

lifileucel + modafinil

monitor HR: combo may incr. risk of tachycardia (additive effects)

• monomethyl fumarate
Amtagvi (lifileucel)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

lifileucel + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of serious infection, GI or other bleeding, incl. life-threatening (additive effects)

• nabumetone
Amtagvi (lifileucel)

+

nabumetone

1 interaction

Monitor/Modify Tx

lifileucel + nabumetone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• naproxen
Amtagvi (lifileucel)

+

naproxen

1 interaction

Monitor/Modify Tx

lifileucel + naproxen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nattokinase
Amtagvi (lifileucel)

+

nattokinase

1 interaction

Monitor/Modify Tx

lifileucel + nattokinase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• neomycin
Amtagvi (lifileucel)

+

neomycin

1 interaction

Monitor/Modify Tx

lifileucel + neomycin

if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• nepafenac ophthalmic
Amtagvi (lifileucel)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• niacin (vitamin B3)
Amtagvi (lifileucel)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

lifileucel + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• nilotinib
Amtagvi (lifileucel)

+

nilotinib

1 interaction

Monitor/Modify Tx

lifileucel + nilotinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nintedanib
Amtagvi (lifileucel)

+

nintedanib

1 interaction

Monitor/Modify Tx

lifileucel + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nortriptyline
Amtagvi (lifileucel)

+

nortriptyline

1 interaction

Monitor/Modify Tx

lifileucel + nortriptyline

monitor HR: combo may incr. risk of tachycardia (additive effects)

• nusinersen
Amtagvi (lifileucel)

+

nusinersen

1 interaction

Monitor/Modify Tx

lifileucel + nusinersen

monitor renal fxn, platelets, bleeding s/sx: combo may incr. risk of nephrotoxicity, bleeding, incl. life-threatening (additive effects)

• olodaterol inhaled
Amtagvi (lifileucel)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + olodaterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• olsalazine
Amtagvi (lifileucel)

+

olsalazine

1 interaction

Monitor/Modify Tx

lifileucel + olsalazine

monitor CBC, renal fxn: combo may incr. risk of nephrotoxicity, myelosuppression (additive effects)

• omega-3-acid
Amtagvi (lifileucel)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

lifileucel + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• orphenadrine
Amtagvi (lifileucel)

+

orphenadrine

1 interaction

Monitor/Modify Tx

lifileucel + orphenadrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• oxaprozin
Amtagvi (lifileucel)

+

oxaprozin

1 interaction

Monitor/Modify Tx

lifileucel + oxaprozin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pacritinib
Amtagvi (lifileucel)

+

pacritinib

1 interaction

Monitor/Modify Tx

lifileucel + pacritinib

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pamidronate
Amtagvi (lifileucel)

+

pamidronate

1 interaction

Monitor/Modify Tx

lifileucel + pamidronate

monitor renal fxn: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

• paromomycin
Amtagvi (lifileucel)

+

paromomycin

1 interaction

Monitor/Modify Tx

lifileucel + paromomycin

if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• paroxetine
Amtagvi (lifileucel)

+

paroxetine

1 interaction

Monitor/Modify Tx

lifileucel + paroxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pazopanib
Amtagvi (lifileucel)

+

pazopanib

1 interaction

Monitor/Modify Tx

lifileucel + pazopanib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• pegaspargase
Amtagvi (lifileucel)

+

pegaspargase

1 interaction

Monitor/Modify Tx

lifileucel + pegaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pegfilgrastim (G-CSF)
Amtagvi (lifileucel)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

lifileucel + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Amtagvi (lifileucel)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

lifileucel + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Amtagvi (lifileucel)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

lifileucel + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pemetrexed
Amtagvi (lifileucel)

+

pemetrexed

1 interaction

Monitor/Modify Tx

lifileucel + pemetrexed

monitor CBC, renal fxn: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• penicillin G
Amtagvi (lifileucel)

+

penicillin G

1 interaction

Monitor/Modify Tx

lifileucel + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pentosan polysulfate sodium
Amtagvi (lifileucel)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

lifileucel + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pentostatin
Amtagvi (lifileucel)

+

pentostatin

1 interaction

Monitor/Modify Tx

lifileucel + pentostatin

monitor CBC, renal fxn: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• pentoxifylline
Amtagvi (lifileucel)

+

pentoxifylline

1 interaction

Monitor/Modify Tx

lifileucel + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• phendimetrazine
Amtagvi (lifileucel)

+

phendimetrazine

1 interaction

Monitor/Modify Tx

lifileucel + phendimetrazine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• phentermine
Amtagvi (lifileucel)

+

phentermine

1 interaction

Monitor/Modify Tx

lifileucel + phentermine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• phenylephrine ophthalmic
Amtagvi (lifileucel)

+

phenylephrine ophthalmic

1 interaction

Monitor/Modify Tx

lifileucel + phenylephrine ophthalmic

monitor HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of tachycardia (additive effects)

• piperacillin
Amtagvi (lifileucel)

+

piperacillin

1 interaction

Monitor/Modify Tx

lifileucel + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• piroxicam
Amtagvi (lifileucel)

+

piroxicam

1 interaction

Monitor/Modify Tx

lifileucel + piroxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pirtobrutinib
Amtagvi (lifileucel)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

lifileucel + pirtobrutinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• plasminogen, human
Amtagvi (lifileucel)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

lifileucel + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• plazomicin
Amtagvi (lifileucel)

+

plazomicin

1 interaction

Monitor/Modify Tx

lifileucel + plazomicin

monitor plazomicin levels, renal fxn, ototoxicity: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• ponatinib
Amtagvi (lifileucel)

+

ponatinib

1 interaction

Monitor/Modify Tx

lifileucel + ponatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• porfimer
Amtagvi (lifileucel)

+

porfimer

1 interaction

Monitor/Modify Tx

lifileucel + porfimer

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pralsetinib
Amtagvi (lifileucel)

+

pralsetinib

1 interaction

Monitor/Modify Tx

lifileucel + pralsetinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• prasugrel
Amtagvi (lifileucel)

+

prasugrel

1 interaction

Monitor/Modify Tx

lifileucel + prasugrel

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• proguanil
Amtagvi (lifileucel)

+

proguanil

1 interaction

Monitor/Modify Tx

lifileucel + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• protriptyline
Amtagvi (lifileucel)

+

protriptyline

1 interaction

Monitor/Modify Tx

lifileucel + protriptyline

monitor HR: combo may incr. risk of tachycardia (additive effects)

• pseudoephedrine
Amtagvi (lifileucel)

+

pseudoephedrine

1 interaction

Monitor/Modify Tx

lifileucel + pseudoephedrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• pyrimethamine
Amtagvi (lifileucel)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

lifileucel + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ramucirumab
Amtagvi (lifileucel)

+

ramucirumab

1 interaction

Monitor/Modify Tx

lifileucel + ramucirumab

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• ranibizumab
Amtagvi (lifileucel)

+

ranibizumab

1 interaction

Monitor/Modify Tx

lifileucel + ranibizumab

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• regorafenib
Amtagvi (lifileucel)

+

regorafenib

1 interaction

Monitor/Modify Tx

lifileucel + regorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• resveratrol
Amtagvi (lifileucel)

+

resveratrol

1 interaction

Monitor/Modify Tx

lifileucel + resveratrol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• Rho(D) immune globulin
Amtagvi (lifileucel)

+

Rho(D) immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + Rho(D) immune globulin

monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ribavirin
Amtagvi (lifileucel)

+

ribavirin

1 interaction

Monitor/Modify Tx

lifileucel + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rifabutin
Amtagvi (lifileucel)

+

rifabutin

1 interaction

Monitor/Modify Tx

lifileucel + rifabutin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rituximab
Amtagvi (lifileucel)

+

rituximab

1 interaction

Monitor/Modify Tx

lifileucel + rituximab

monitor CBC, renal fxn: combo may incr. risk of myelosuppression, nephrotoxicity (additive effects)

• rotigotine transdermal
Amtagvi (lifileucel)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

lifileucel + rotigotine transdermal

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ruxolitinib topical
Amtagvi (lifileucel)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

lifileucel + ruxolitinib topical

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• salmeterol inhaled
Amtagvi (lifileucel)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + salmeterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• salsalate
Amtagvi (lifileucel)

+

salsalate

1 interaction

Monitor/Modify Tx

lifileucel + salsalate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sargramostim (GM-CSF)
Amtagvi (lifileucel)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

lifileucel + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Amtagvi (lifileucel)

+

sarilumab

1 interaction

Monitor/Modify Tx

lifileucel + sarilumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• satralizumab
Amtagvi (lifileucel)

+

satralizumab

1 interaction

Monitor/Modify Tx

lifileucel + satralizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• saw palmetto
Amtagvi (lifileucel)

+

saw palmetto

1 interaction

Monitor/Modify Tx

lifileucel + saw palmetto

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• selpercatinib
Amtagvi (lifileucel)

+

selpercatinib

1 interaction

Monitor/Modify Tx

lifileucel + selpercatinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• selumetinib
Amtagvi (lifileucel)

+

selumetinib

1 interaction

Monitor/Modify Tx

lifileucel + selumetinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sertraline
Amtagvi (lifileucel)

+

sertraline

1 interaction

Monitor/Modify Tx

lifileucel + sertraline

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• sirolimus albumin-bound
Amtagvi (lifileucel)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

lifileucel + sirolimus albumin-bound

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• sitagliptin
Amtagvi (lifileucel)

+

sitagliptin

1 interaction

Monitor/Modify Tx

lifileucel + sitagliptin

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• solriamfetol
Amtagvi (lifileucel)

+

solriamfetol

1 interaction

Monitor/Modify Tx

lifileucel + solriamfetol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• sorafenib
Amtagvi (lifileucel)

+

sorafenib

1 interaction

Monitor/Modify Tx

lifileucel + sorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sotatercept
Amtagvi (lifileucel)

+

sotatercept

1 interaction

Monitor/Modify Tx

lifileucel + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. severe or life-threatening (additive effects)

• sparsentan
Amtagvi (lifileucel)

+

sparsentan

1 interaction

Monitor/Modify Tx

lifileucel + sparsentan

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• stiripentol
Amtagvi (lifileucel)

+

stiripentol

1 interaction

Monitor/Modify Tx

lifileucel + stiripentol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succimer
Amtagvi (lifileucel)

+

succimer

1 interaction

Monitor/Modify Tx

lifileucel + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Amtagvi (lifileucel)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

lifileucel + sulfasalazine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• sulindac
Amtagvi (lifileucel)

+

sulindac

1 interaction

Monitor/Modify Tx

lifileucel + sulindac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sunitinib
Amtagvi (lifileucel)

+

sunitinib

1 interaction

Monitor/Modify Tx

lifileucel + sunitinib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• telavancin
Amtagvi (lifileucel)

+

telavancin

1 interaction

Monitor/Modify Tx

lifileucel + telavancin

monitor ECG, renal fxn: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

• temsirolimus
Amtagvi (lifileucel)

+

temsirolimus

1 interaction

Monitor/Modify Tx

lifileucel + temsirolimus

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• tenofovir alafenamide
Amtagvi (lifileucel)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

lifileucel + tenofovir alafenamide

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• teplizumab
Amtagvi (lifileucel)

+

teplizumab

1 interaction

Monitor/Modify Tx

lifileucel + teplizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• terbutaline
Amtagvi (lifileucel)

+

terbutaline

1 interaction

Monitor/Modify Tx

lifileucel + terbutaline

monitor HR: combo may incr. risk of tachycardia (additive effects)

• teriflunomide
Amtagvi (lifileucel)

+

teriflunomide

1 interaction

Monitor/Modify Tx

lifileucel + teriflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• thalidomide
Amtagvi (lifileucel)

+

thalidomide

1 interaction

Monitor/Modify Tx

lifileucel + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ticagrelor
Amtagvi (lifileucel)

+

ticagrelor

1 interaction

Monitor/Modify Tx

lifileucel + ticagrelor

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tiopronin
Amtagvi (lifileucel)

+

tiopronin

1 interaction

Monitor/Modify Tx

lifileucel + tiopronin

monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

• tipranavir
Amtagvi (lifileucel)

+

tipranavir

1 interaction

Monitor/Modify Tx

lifileucel + tipranavir

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tirofiban
Amtagvi (lifileucel)

+

tirofiban

1 interaction

Monitor/Modify Tx

lifileucel + tirofiban

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tisotumab vedotin
Amtagvi (lifileucel)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

lifileucel + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tivozanib
Amtagvi (lifileucel)

+

tivozanib

1 interaction

Monitor/Modify Tx

lifileucel + tivozanib

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• tocilizumab
Amtagvi (lifileucel)

+

tocilizumab

1 interaction

Monitor/Modify Tx

lifileucel + tocilizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• tofacitinib
Amtagvi (lifileucel)

+

tofacitinib

1 interaction

Monitor/Modify Tx

lifileucel + tofacitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• tolmetin
Amtagvi (lifileucel)

+

tolmetin

1 interaction

Monitor/Modify Tx

lifileucel + tolmetin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tovorafenib
Amtagvi (lifileucel)

+

tovorafenib

1 interaction

Monitor/Modify Tx

lifileucel + tovorafenib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• trametinib
Amtagvi (lifileucel)

+

trametinib

1 interaction

Monitor/Modify Tx

lifileucel + trametinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• trazodone
Amtagvi (lifileucel)

+

trazodone

1 interaction

Monitor/Modify Tx

lifileucel + trazodone

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• treprostinil
Amtagvi (lifileucel)

+

treprostinil

1 interaction

Monitor/Modify Tx

lifileucel + treprostinil

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• trimethoprim
Amtagvi (lifileucel)

+

trimethoprim

1 interaction

Monitor/Modify Tx

lifileucel + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• trimipramine
Amtagvi (lifileucel)

+

trimipramine

1 interaction

Monitor/Modify Tx

lifileucel + trimipramine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• trospium
Amtagvi (lifileucel)

+

trospium

1 interaction

Monitor/Modify Tx

lifileucel + trospium

monitor HR: combo may incr. risk of tachycardia (additive effects)

• upadacitinib
Amtagvi (lifileucel)

+

upadacitinib

1 interaction

Monitor/Modify Tx

lifileucel + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• vaccinia immune globulin
Amtagvi (lifileucel)

+

vaccinia immune globulin

1 interaction

Monitor/Modify Tx

lifileucel + vaccinia immune globulin

monitor renal fxn; use lowest vaccinia immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• vadadustat
Amtagvi (lifileucel)

+

vadadustat

1 interaction

Monitor/Modify Tx

lifileucel + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• valacyclovir
Amtagvi (lifileucel)

+

valacyclovir

1 interaction

Monitor/Modify Tx

lifileucel + valacyclovir

monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• valproic acid
Amtagvi (lifileucel)

+

valproic acid

1 interaction

Monitor/Modify Tx

lifileucel + valproic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, incl. life-threatening (additive effects)

• vancomycin
Amtagvi (lifileucel)

+

vancomycin

1 interaction

Monitor/Modify Tx

lifileucel + vancomycin

VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)

• vandetanib
Amtagvi (lifileucel)

+

vandetanib

1 interaction

Monitor/Modify Tx

lifileucel + vandetanib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• venlafaxine
Amtagvi (lifileucel)

+

venlafaxine

1 interaction

Monitor/Modify Tx

lifileucel + venlafaxine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vilanterol inhaled
Amtagvi (lifileucel)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

lifileucel + vilanterol inhaled

monitor HR: combo may incr. risk of tachycardia (additive effects)

• vilazodone
Amtagvi (lifileucel)

+

vilazodone

1 interaction

Monitor/Modify Tx

lifileucel + vilazodone

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• viloxazine
Amtagvi (lifileucel)

+

viloxazine

1 interaction

Monitor/Modify Tx

lifileucel + viloxazine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• vinpocetine
Amtagvi (lifileucel)

+

vinpocetine

1 interaction

Monitor/Modify Tx

lifileucel + vinpocetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• vorapaxar
Amtagvi (lifileucel)

+

vorapaxar

1 interaction

Monitor/Modify Tx

lifileucel + vorapaxar

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• vortioxetine
Amtagvi (lifileucel)

+

vortioxetine

1 interaction

Monitor/Modify Tx

lifileucel + vortioxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• willow bark
Amtagvi (lifileucel)

+

willow bark

1 interaction

Monitor/Modify Tx

lifileucel + willow bark

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, willow bark may contain salicylates)

• yohimbe
Amtagvi (lifileucel)

+

yohimbe

1 interaction

Monitor/Modify Tx

lifileucel + yohimbe

monitor HR: combo may incr. risk of tachycardia (additive effects)

• zanubrutinib
Amtagvi (lifileucel)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

lifileucel + zanubrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• zidovudine
Amtagvi (lifileucel)

+

zidovudine

1 interaction

Monitor/Modify Tx

lifileucel + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziv-aflibercept
Amtagvi (lifileucel)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

lifileucel + ziv-aflibercept

monitor renal fxn, bleeding s/sx: combo may incr. risk of nephrotoxicity, GI or other bleeding, incl. life-threatening (additive effects)

• zoledronic acid
Amtagvi (lifileucel)

+

zoledronic acid

1 interaction

Monitor/Modify Tx

lifileucel + zoledronic acid

monitor renal fxn: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)